Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.68 |
| ▸ | RELA | Q04206 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | ESRRG | P62508 | 4/20 | 0.62 |
| ▸ | ESRRB | O95718 | 1/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL620074 | 0.86 | POLB (0.66) | MAPK1HPGDNFKB1LMNAALDH1A1 | |
| SCHEMBL9490980 | 0.85 | SMN1; SMN2 (0.73) | RAB9ANPC1SMN1; SMN2MAPK1TP53 | |
| SCHEMBL14615882 | 0.85 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2MAPK1TP53 | |
| SCHEMBL10606216 | 0.85 | EPHX2 (0.65) | RAB9ANPC1SMN1; SMN2MAPK1TP53 | |
| SCHEMBL13762059 | 0.84 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2MAPK1TP53 | |
| SCHEMBL25754119 | 0.84 | MMP13 (0.55) | RAB9ANPC1SMN1; SMN2MAPK1TP53 | |
| SCHEMBL13762062 | 0.84 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2MAPK1TP53 | |
| SCHEMBL12243059 | 0.84 | MLYCD (0.69) | RAB9ANPC1SMN1; SMN2MAPK1TP53 | |
| SCHEMBL10795254 | 0.84 | MEN1 (0.57) | RAB9ANPC1SMN1; SMN2MAPK1TP53 | |
| SCHEMBL12139852 | 0.84 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2MAPK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315494-B2 | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-19 | — | — | US | disclosed |
| US-9193731-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150307483-A1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-29 | — | — | US | disclosed |
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| EP-1208175-B1 | MIXTURES OF beta-HYDROXYALKYL AMIDES AND THEIR USE AS CROSS-LINKING AGENTS FOR THE PREPARATION OF POWDER PAINTS | SIR IND SPA (IT) | 2006-05-17 | — | — | EP | disclosed |
| US-6767479-B1 | THERMOSETTING WITHOUT USE OF HIGH QUANTITIES OF DEGASSING ADDITIVES; MAINTAINING GOOD MECHANICAL AND AESTHETIC CHARACTERISTICS | SIR INDUSTRIALE S.P.A. (IT) | 2004-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307483-A1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | IFNG, TYK2, IFNAR1 | RAB9A 2089/4885NPC1 4872/4885SMN1; SMN2 3661/4885 |
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | RAB9A 3216/4885NPC1 985/4885SMN1; SMN2 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.